30 closest matches · ranked by relevance
Elranatamab · Myeloma · Multiple Myeloma
Primary: Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) — 1 Participants
Relapsed or Refractory Multiple Myeloma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0 Participants
Multiple Myeloma
Primary: Number of Participants With Grade 2 or Higher Cytokine Release Syndrome (CRS) During Cycle 1: Parts 1 and 2 — 12 Participants
Multiple Myeloma
Primary: Overall Survival (OS): C1071003 Cohort A Versus TM-MM Database Using Inverse Probability of Treatment Weights (IPTW) Analysis — 13.27; 14.29 Months — p==0.615
Multiple Myeloma
Primary: Objective Response Rate (ORR)-Unweighted Analysis — 61.0; 31.3; 30.3 Percentage of participants — p=<.0001
Multiple Myeloma
Primary: Progression Free Survival (PFS): Study C1071003 Cohort A Versus RWD COTA Cohort- Using Unweighted Analysis — NA; 4.70 Months — p=<.0001
AL Amyloidosis
Primary: Assess the Number of Patients Who Respond to Treatment — 5; 13; 2; 1 Participants
Multiple Myeloma
Primary: Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0 Participants
Neuroblastoma
Primary: MTD/RP2D Determination A1 — 0; 0; 0; 0 Participants
POEMS Syndrome
Primary: Treatment Success — 0 Participants
Aplastic Anemia
Primary: ORR at 6 Months: Overall Response Rate (ORR) Defined as the Number of Participants Who Met the Criteria of Either Complete Response (CR) or Partial Response (PR) at Week…
Metastatic Non Small Cell Lung Cancer · Recurrent Non Small Cell Lung Cancer
Primary: Overall Objective Response Rate — 2; 17; 18 Participants
Chronic Lymphocytic Leukemia
Primary: Rate of Complete Remission/Complete Remission With Incomplete Recovery of the Bone Marrow (CR/CRi), as Assessed by Investigator Using Modified International Workshop on…
Multiple Myeloma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs), Treatment A — 0; 0; 0 Participants
Multiple Myeloma
Primary: Induction Feasibility Rate (IFR) — 33 Participants
Acute Myeloid Leukemia · Myeloid Leukemia · Monocytic Leukemia
Primary: Number of Participants Experiencing Dose Limiting Toxicity (DLT) Events — 0; 0; 0; 0 Count of Participants
Immune Thrombocytopenia
Primary: Part A: Percentage of Participants Who Achieved 2 or More Consecutive Platelet Counts by Starting Dose Level and Overall — 44.4; 0.0; 40.0; 40.0 percentage of participants
Lymphoma, Non-Hodgkin · Lymphoma, Nonhodgkin · Lymphoma, B-Cell
Primary: Overall Response Rate (ORR) — 80.3 Percent of Participants — p=<.0001
In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India
Primary: Participants With Adverse Events (AEs), Serious AEs, and Treatment-emergent AEs — 44; 5; 43; 1 Participants
Colon Cancer · Colorectal Cancer · Gastrointestinal Cancer
Primary: Part 1: Number of Participants With Dose-limiting Toxicities (DLT) — 0 participants
Breast Cancer
Primary: Percentage of Participants With a Cardiac Event Within 12 Weeks After the Start of Trastuzumab Emtansine Treatment — 0 Percentage of participants
Adult T-Cell Lymphoma (ATL)
Primary: Objective Response Rate — 7 Participants
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Proportion Of Participants With Normalization Of Lactate Dehydrogenase (LDH) Levels — 0.536; 0.494 proportion of participants
Atopic Dermatitis
Primary: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade…
B-cell Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Mantle Cell Lymphoma
Primary: Overall Response — 3; 3; 3; 2 Participants
HIV-1 Infection
Primary: Primary Cohort: Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs) — 0; 0 percentage of participants
Severe Aplastic Anemia (SAA)
Primary: Complete Response (CR) Rate at Week 26 — 16.7; 25; 15.4; 0 percentage of participants
Breast Cancer
Primary: Objective Response Rate (ORR) (Phase II) — 0; 5; 14 Participants
Oncology · Melanoma · Ovarian Cancer
Primary: Number of Participants Who Experienced AEs or SAEs — 5; 4; 8; 15 Participants
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Percent Change In Lactate Dehydrogenase Levels From Baseline To Day 183 — -0.82; 8.39 percent change